Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9699973 | 0.98 | POLB (0.64) | POLBTDP1NPC1CYP2C19HPGD | |
| Trifluoroacetic Acid SCHEMBL27502765 | 0.91 | TDP1 (0.57) | POLBTDP1NPC1CYP2C19HPGD | |
| SCHEMBL28899113 | 0.91 | NPC1 (0.67) | POLBTDP1NPC1CYP2C19HPGD | |
| SCHEMBL338927 | 0.88 | NPC1 (0.68) | POLBTDP1NPC1CYP2C19HPGD | |
| Isobutyramide SCHEMBL28394293 | 0.87 | POLB (0.53) | POLBTDP1NPC1CYP2C19HPGD | |
| SCHEMBL2400084 | 0.86 | NPC1 (0.70) | POLBTDP1NPC1CYP2C19HPGD | |
| Hydrochloric Acid SCHEMBL11633870 | 0.86 | NPC1 (0.66) | POLBTDP1NPC1CYP2C19HPGD | |
| SCHEMBL7332254 | 0.85 | TAAR1 (0.54) | POLBTDP1NPC1CYP2C19HPGD | |
| SCHEMBL4368662 | 0.85 | NPC1 (0.68) | POLBTDP1NPC1CYP2C19HPGD | |
| SCHEMBL4365322 | 0.85 | NPC1 (0.68) | POLBTDP1NPC1CYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110698456-B | Synthesis method of 2, 3-dihydrothiochromen-4-one and derivatives thereof | 重庆医药高等专科学校 | 2021-05-14 | — | — | CN | claimed |
| CN-110127869-B | Environment-friendly neutral scale and corrosion inhibitor for oil extraction and preparation method thereof | 黑龙江益瑞化工有限公司 | 2020-10-09 | — | — | CN | claimed |
| WO-2009055631-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-30 | — | — | WO | claimed |
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | YUEN PO-WAI (US) | 2004-07-01 | — | — | US | claimed |
| JP-2003500486-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1185524-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2000073296-A2 | 3-HETEROARYLALKYL SUBSTITUTED GABA ANALOGS | WARNER-LAMBERT COMPANY (US) | 2000-12-07 | — | — | WO | claimed |
| US-5574016-A | Peptide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-12 | — | — | US | claimed |
| EP-0124407-B1 | PROCESS FOR THE PREPARATION OF ALKANOIC ACIDS | SOCIETE FRANCAISE HOECHST Société anonyme dite: (FR) | 1989-08-23 | — | — | EP | claimed |
| US-4515970-A | Process for preparation of alkanoic acids | SOCIETE FRANCAISE HOECHST (FR) | 1985-05-07 | — | — | US | claimed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-12440444-B2 | Matrix bound vesicles (MBVS) containing IL-33 and their use | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-10-14 | — | — | US | disclosed |
| CN-114763346-B | Compounds for inducing cartilage formation and application thereof | 华东师范大学 | 2025-06-10 | — | — | CN | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| CN-119319248-B | Silver-coated copper powder and preparation method thereof, conductive paste and printed RFID tag | 浙江码尚科技股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-4159986-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | ROUSSEL UCLAF (FR) | 1979-07-03 | — | — | US | disclosed |
| US-4127665-A | ALDOSE REDUCTASE INHIBITORS, TREATMENT OF CHROMIC DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4097485-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
| US-4086241-A | Benzothiazolylimidazolidinone esters of furyl and thienyl substituted acids | VELSICOL CHEMICAL CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4061648-A | HERBICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127724-A1 | 3-heteroarylalkyl substituted GABA analogs | GABRB3, GABRB1, GABRB2 | POLB 2802/4885TDP1 2634/4885NPC1 2019/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | POLB 1619/4885TDP1 3895/4885NPC1 714/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | POLB 4851/4885TDP1 4630/4885NPC1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.